The epidermal growth factor receptor 2 (HER2, also known as ERBB2), a member of the HER family of receptor tyrosine kinases, is overexpressed in 15–20% of primary breast cancers including 10% of estrogen receptor (ER)-positive breast cancers [1, 2]. Here, ERBB2 is linked to breast carcinoma.